Gujarat Inject Kerala Share Price
Sector: Biotechnology & Drugs
24.55 -0.61 (-2.42%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
24.10
Today’s High
26.25
52 Week Low
13.11
52 Week High
29.12
Key Metrics
- Market Cap (In Cr) 35.81
- Beta -
- Div. Yield (%) 0
- P/B 2.77
- TTM P/E 37.68
- Sector P/E 0
- Open Price 25.99
- Prev Close 25.16
Gujarat Inject Kerala Analysis
Price Analysis
-
1 Week-3.46%
-
3 Months-5.58%
-
6 Month6.55%
-
YTD-3.31%
-
1 Year46.57%
Risk Meter
- 57% Low risk
- 57% Moderate risk
- 57% Balanced Risk
- 57% High risk
- 57% Extreme risk
Gujarat Inject Kerala Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 19.05
- Selling/ General/ Admin Expenses Total
- 0.06
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.13
- Total Operating Expense
- 17.97
- Operating Income
- 1.08
- Net Income Before Taxes
- 1.25
- Net Income
- 1.02
- Diluted Normalized EPS
- 0.7
- Period
- 2025
- Total Assets
- 11.95
- Total Liabilities
- 1.94
- Total Equity
- 10.01
- Tangible Book Valueper Share Common Eq
- 8.86
- Period
- 2025
- Cashfrom Operating Activities
- -3.52
- Cashfrom Investing Activities
- 0
- Cashfrom Financing Activities
- 0.63
- Net Changein Cash
- -2.89
- Period
- 2024
- Total Revenue
- 5.79
- Selling/ General/ Admin Expenses Total
- 0.03
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.31
- Total Operating Expense
- 5.74
- Operating Income
- 0.04
- Net Income Before Taxes
- 0.11
- Net Income
- 0.08
- Diluted Normalized EPS
- 0.09
- Period
- 2024
- Total Assets
- 8.69
- Total Liabilities
- 0.14
- Total Equity
- 8.55
- Tangible Book Valueper Share Common Eq
- 7.56
- Period
- 2024
- Cashfrom Operating Activities
- -6.03
- Cashfrom Investing Activities
- 0
- Cashfrom Financing Activities
- 8.88
- Net Changein Cash
- 2.86
- Period
- 2023
- Total Revenue
- 0.17
- Selling/ General/ Admin Expenses Total
- 0.03
- Other Operating Expenses Total
- 0.37
- Total Operating Expense
- 0.55
- Operating Income
- -0.38
- Net Income Before Taxes
- 0.06
- Net Income
- 0.04
- Diluted Normalized EPS
- 0.08
- Period
- 2023
- Total Assets
- 0.3
- Total Liabilities
- 1.14
- Total Equity
- -0.84
- Tangible Book Valueper Share Common Eq
- -1.71
- Period
- 2023
- Cashfrom Operating Activities
- 0.05
- Cashfrom Investing Activities
- 0
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- 0.05
- Period
- 2022
- Total Revenue
- 0.02
- Selling/ General/ Admin Expenses Total
- 0.01
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.04
- Total Operating Expense
- 0.07
- Operating Income
- -0.05
- Net Income Before Taxes
- 0
- Net Income
- 0
- Diluted Normalized EPS
- 0
- Period
- 2022
- Total Assets
- 0.06
- Total Liabilities
- 0.94
- Total Equity
- -0.88
- Tangible Book Valueper Share Common Eq
- -1.79
- Period
- 2022
- Cashfrom Operating Activities
- 0
- Cashfrom Investing Activities
- 0
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- 0
- Period
- 2021
- Total Revenue
- 0.01
- Selling/ General/ Admin Expenses Total
- 0
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.11
- Total Operating Expense
- 0.12
- Operating Income
- -0.11
- Net Income Before Taxes
- -0.11
- Net Income
- -0.11
- Diluted Normalized EPS
- -0.21
- Period
- 2021
- Total Assets
- 0.02
- Total Liabilities
- 0.9
- Total Equity
- -0.88
- Tangible Book Valueper Share Common Eq
- -1.8
- Period
- 2021
- Cashfrom Operating Activities
- -0.11
- Cashfrom Investing Activities
- 0
- Cashfrom Financing Activities
- 0.1
- Net Changein Cash
- 0
- Period
- 2020
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 0.01
- Operating Income
- -0.01
- Net Income Before Taxes
- 0
- Net Income
- 0
- Diluted Normalized EPS
- 0
- Period
- 2020
- Total Assets
- 0.01
- Total Liabilities
- 0.79
- Total Equity
- -0.78
- Tangible Book Valueper Share Common Eq
- -1.58
- Period
- 2020
- Cashfrom Operating Activities
- 0
- Cashfrom Investing Activities
- 0
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- 0
- Period
- 2019
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0.01
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.01
- Total Operating Expense
- 0.02
- Operating Income
- -0.02
- Net Income Before Taxes
- -0.01
- Net Income
- -0.01
- Diluted Normalized EPS
- -0.01
- Period
- 2019
- Total Assets
- 0.01
- Total Liabilities
- 0.79
- Total Equity
- -0.78
- Tangible Book Valueper Share Common Eq
- -1.58
- Period
- 2019
- Cashfrom Operating Activities
- 0
- Cashfrom Investing Activities
- 0
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- 0
- Period
- 2025-03-31
- Total Revenue
- 4.24
- Selling/ General/ Admin Expenses Total
- 0.03
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0
- Total Operating Expense
- 4.15
- Operating Income
- 0.09
- Net Income Before Taxes
- 0.1
- Net Income
- 0.07
- Diluted Normalized EPS
- 0.05
- Period
- 2025-03-31
- Total Assets
- 11.95
- Total Liabilities
- 1.94
- Total Equity
- 10.01
- Tangible Book Valueper Share Common Eq
- 8.86
- Period
- 2025-03-31
- Cashfrom Operating Activities
- -3.52
- Cashfrom Investing Activities
- 0
- Cashfrom Financing Activities
- 0.63
- Net Changein Cash
- -2.89
- Period
- 2024-12-31
- Total Revenue
- 3.15
- Selling/ General/ Admin Expenses Total
- 0.01
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.01
- Total Operating Expense
- 2.87
- Operating Income
- 0.28
- Net Income Before Taxes
- 0.28
- Net Income
- 0.21
- Diluted Normalized EPS
- 0.14
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 8.61
- Selling/ General/ Admin Expenses Total
- 0.01
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.01
- Total Operating Expense
- 8.07
- Operating Income
- 0.54
- Net Income Before Taxes
- 0.71
- Net Income
- 0.61
- Diluted Normalized EPS
- 0.42
- Period
- 2024-09-30
- Total Assets
- 14.23
- Total Liabilities
- 4.5
- Total Equity
- 9.73
- Tangible Book Valueper Share Common Eq
- 6.65
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -3.38
- Cashfrom Investing Activities
- 0.17
- Cashfrom Financing Activities
- 0.45
- Net Changein Cash
- -2.77
- Period
- 2024-06-30
- Total Revenue
- 3.05
- Selling/ General/ Admin Expenses Total
- 0.01
- Other Operating Expenses Total
- 0.11
- Total Operating Expense
- 2.88
- Operating Income
- 0.17
- Net Income Before Taxes
- 0.17
- Net Income
- 0.12
- Diluted Normalized EPS
- 0.08
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 5.42
- Selling/ General/ Admin Expenses Total
- 0.02
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.21
- Total Operating Expense
- 5.37
- Operating Income
- 0.05
- Net Income Before Taxes
- 0.05
- Net Income
- 0.04
- Diluted Normalized EPS
- 0.02
- Period
- 2024-03-31
- Total Assets
- 8.69
- Total Liabilities
- 0.14
- Total Equity
- 8.55
- Tangible Book Valueper Share Common Eq
- 7.56
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -6.03
- Cashfrom Investing Activities
- 0
- Cashfrom Financing Activities
- 8.88
- Net Changein Cash
- 2.86
- Period
- 2023-12-31
- Total Revenue
- 0.22
- Selling/ General/ Admin Expenses Total
- 0
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.09
- Total Operating Expense
- 0.25
- Operating Income
- -0.03
- Net Income Before Taxes
- 0.01
- Net Income
- 0
- Diluted Normalized EPS
- 0.01
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Gujarat Inject Kerala Technical
Moving Average
SMA
- 5 Day25.26
- 10 Day23.73
- 20 Day24.18
- 50 Day22.56
- 100 Day24.61
- 300 Day24.03
Gujarat Inject Kerala Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Medico Intercontinental
- 39.48
- 1.38
- 3.62
- 63.59
- 34
- 38.58
- Gujarat Terce Laboratories
- 53
- 1.85
- 3.62
- 94.9
- 44.52
- 39.4
- Gujarat Inject Kerala
- 24.55
- -0.61
- -2.42
- 29.12
- 13.11
- 35.81
- Veerhealth Care
- 18.54
- 0.26
- 1.42
- 27
- 9.29
- 36.94
- Ang Lifesciences India
- 28
- 0.17
- 0.61
- 62.75
- 21.03
- 36.56
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Medico Intercontinental
- 7.53
- 0.78
- 14.32
- 4.72
- Gujarat Terce Laboratories
- -
- 5.86
- -10.41
- -1.93
- Gujarat Inject Kerala
- 35.94
- 2.84
- 9.82
- 4.14
- Veerhealth Care
- 91.4
- 1.65
- 3.01
- 4.24
- Ang Lifesciences India
- -
- 0.57
- 7.28
- 2.53
Gujarat Inject Kerala Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 20-May-25
- Audited Results
- 18-Feb-25
- Stock Split
- 23-Jan-25
- Quarterly Results
- 22-Oct-24
- Quarterly Results
- 10-Aug-24
- Quarterly Results
- 09-May-24
- Audited Results
- 13-Feb-24
- Quarterly Results
- 22-Nov-23
- Others
- 06-Nov-23
- Quarterly Results
- 03-Nov-23
- Quarterly Results & Preferential issue
- Meeting Date
- Announced on
- Purpose
- 03-Apr-25
- 13-Mar-25
- EGM
- 28-Sept-24
- 16-Sept-24
- AGM
- 20-Jan-24
- 28-Dec-23
- EGM
- 30-Sept-23
- 15-Sept-23
- AGM
- 29-Sept-21
- 12-Aug-21
- AGM
- 30-Sept-19
- 04-Sept-19
- AGM


- Ex-Splits
- Old FV
- New FV
- Description
- -
- 10
- 1
- Stock split from Rs. 10/- to Re. 1/-.
